ISDA: 7UKR

Deposition Date 2022-04-01

Release Date 2022-07-27

Last Version Date 2023-10-18

Entry Detail

PDB ID:

7UKR

Keywords:

SIGNALING PROTEIN/INHIBITOR

Title:

Crystal Structure of SOS1 with MRTX0902, a Potent and Selective Inhibitor of the SOS1:KRAS Protein-Protein Interaction

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.28

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Son of sevenless homolog 1
Gene (Uniprot):SOS1
Chain IDs:A, B
Chain Length:487
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q07889 Pfam ID:PF00617, PF00618

Ligand Molecules

NKF

Primary Citation

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Ketcham, J.M, Haling, J, Khare, S, Bowcut, V, Briere, D.M, Burns, A.C, Gunn, R.J, Ivetac, A, Kuehler, J, Kulyk, S, Laguer, J, Lawson, J.D, Moya, K, Nguyen, N, Rahbaek, L, Saechao, B, Smith, C.R, Sudhakar, N, Thomas, N.C, Vegar, L, Vanderpool, D, Wang, X, Yan, L, Olson, P, Christensen, J.G, Marx, M.A.Show

J.Med.Chem. 65 9678 9690 (2022)

PMID: 35833726 DOI: 10.1021/acs.jmedchem.2c00741

Abstact

SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRASG12C protein-protein interaction (PPI) can increase the proportion of GDP-loaded KRASG12C, providing a strong mechanistic rationale for combining inhibitors of the SOS1:KRAS complex with inhibitors like MRTX849 that target GDP-loaded KRASG12C. In this report, we detail the design and discovery of MRTX0902─a potent, selective, brain-penetrant, and orally bioavailable SOS1 binder that disrupts the SOS1:KRASG12C PPI. Oral administration of MRTX0902 in combination with MRTX849 results in a significant increase in antitumor activity relative to that of either single agent, including tumor regressions in a subset of animals in the MIA PaCa-2 tumor mouse xenograft model.

Legend

Protein

Chemical

Disease

Primary Citation of related structures